Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2021

Open Access 01-12-2021 | Positron Emission Tomography | Review Article

Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain

Authors: Catriona Wimberley, Sonia Lavisse, Ansel Hillmer, Rainer Hinz, Federico Turkheimer, Paolo Zanotti-Fregonara

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2021

Login to get access

Abstract

Purpose

Translocator protein 18-kDa (TSPO) imaging with positron emission tomography (PET) is widely used in research studies of brain diseases that have a neuro-immune component. Quantification of TSPO PET images, however, is associated with several challenges, such as the lack of a reference region, a genetic polymorphism affecting the affinity of the ligand for TSPO, and a strong TSPO signal in the endothelium of the brain vessels. These challenges have created an ongoing debate in the field about which type of quantification is most useful and whether there is an appropriate simplified model.

Methods

This review focuses on the quantification of TSPO radioligands in the human brain. The various methods of quantification are summarized, including the gold standard of compartmental modeling with metabolite-corrected input function as well as various alternative models and non-invasive approaches. Their advantages and drawbacks are critically assessed.

Results and conclusions

Researchers employing quantification methods for TSPO should understand the advantages and limitations associated with each method. Suggestions are given to help researchers choose between these viable alternative methods.
Literature
1.
DiSabato DJ, Quan N, Godbout JP. Neuroinflammation: the devil is in the details. Journal of Neurochemistry. John Wiley & Sons, Ltd. 2016;139 Suppl 2:136–53.PubMedCrossRef
2.
Nutma E, Ceyzériat K, Amor S, Tsartsalis S, Millet P, Owen DRJ, et al. Cellular sources of TSPO expression in healthy and diseased brain. Eur. J. Nucl. Med. Mol. Imaging. Springer Berlin Heidelberg. 2021;194:44–18.
3.
Junck L, Olson JM, Ciliax BJ, Koeppe RA, Watkins GL, Jewett DM, et al. PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann Neurol. 1989;26:752–8.PubMedCrossRef
4.
Banati RB, Myers R, Kreutzberg GW. PK (“peripheral benzodiazepine”) – binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H] PK 11195 binding to activated microglia. J Neurocytol. 1997;26:77–82.PubMedCrossRef
5.
Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer FE, Heppner F, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis. Brain. 2000;123:2321–37.PubMedCrossRef
6.
van der Laken CJ, Elzinga EH, Kropholler MA, Molthoff CFM, van der Heijden JW, Maruyama K, et al. Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-(R)-PK11195 and positron emission tomography. Arthritis Rheum. 2008;58:3350–5.PubMedCrossRef
7.
Cumming P, Burgher B, Patkar O, Breakspear M, Vasdev N, Thomas P, et al. Sifting through the surfeit of neuroinflammation tracers. J Cereb Blood Flow Metab. 2017;38:204–24.PubMedPubMedCentralCrossRef
8.
Brown AK, Fujita M, Fujimura Y, Liow J-S, Stabin M, Ryu YH, et al. Radiation dosimetry and biodistribution in monkey and man of 11C-PBR28: a PET radioligand to image inflammation. J. Nucl. Med. Society of Nuclear Medicine. 2007;48:2072–9.CrossRef
9.
Arlicot N, Vercouillie J, Ribeiro M-J, Tauber C, Venel Y, Baulieu J-L, et al. Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. Nucl Med Biol Elsevier. 2012;39:570–8.CrossRef
10.
Zanotti-Fregonara P, Zhang Y, Jenko KJ, Gladding RL, Zoghbi SS, Fujita M, et al. Synthesis and evaluation of translocator 18 kDa protein (TSPO) positron emission tomography (PET) radioligands with low binding sensitivity to human single nucleotide polymorphism rs6971. ACS Chem Neurosci American Chemical Society. 2014;5:963–71.CrossRef
11.
Turkheimer FE, Rizzo G, Bloomfield PS, Howes O, Zanotti-Fregonara P, Bertoldo A, et al. The methodology of TSPO imaging with positron emission tomography. Biochem Soc Trans Portland Press Limited. 2015;43:586–92.PubMedPubMedCentralCrossRef
12.
Kanegawa N, Collste K, Forsberg A, Schain M, Arakawa R, Jucaite A, et al. In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects. Brain Behav Immun. 2016;54:149–57.PubMedCrossRef
13.
Kreisl WC, Jenko KJ, Hines CS, Lyoo CH, Corona W, Morse CL, et al. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J. Cereb. Blood Flow Metab. SAGE PublicationsSage UK: London, England. 2013;33:53–8.PubMedCrossRef
14.
Owen DRJ, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32:1–5.PubMedCrossRef
15.
Rizzo G, Veronese M, Tonietto M, Zanotti-Fregonara P, Turkheimer FE, Bertoldo A. Kinetic modeling without accounting for the vascular component impairs the quantification of [(11)C]PBR28 brain PET data. J Cereb Blood Flow Metab 2014.
16.
Kropholler MA, Boellaard R, Schuitemaker A, van Berckel BNM, Luurtsema G, Windhorst AD, et al. Development of a tracer kinetic plasma input model for (R)-[11C]PK11195 brain studies. J. Cereb. Blood Flow Metab. SAGE Publications. 2005;25:842–51.CrossRef
17.
Hannestad J, DellaGioia N, Gallezot J-D, Lim K, Nabulsi N, Esterlis I, et al. The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [11C]PBR28 PET study. Brain Behav Immun. 2013;33:131–8.PubMedPubMedCentralCrossRef
18.
Fujimura Y, Zoghbi SS, Simèon FG, Taku A, Pike VW, Innis R, et al. Quantification of translocator protein (18 kDa) in the human brain with PET and a novel radioligand, (18)F-PBR06. J. Nucl. Med. Society of Nuclear Medicine. 2009;50:1047–53.CrossRef
19.
Koshimori Y, Ko JH, Mizrahi R, Rusjan P, Mabrouk R, Jacobs MF, et al. Imaging striatal microglial activation in patients with Parkinson’s disease. Tansey MG, editor. PLoS ONE. Public Libr Sci. 2015;10:e0138721.PubMedPubMedCentralCrossRef
20.
Suridjan I, Rusjan PM, Kenk M, Verhoeff NPLG, Voineskos AN, Rotenberg D, et al. Quantitative imaging of neuroinflammation in human white matter: a positron emission tomography study with translocator protein 18 kDa radioligand, [18F]-FEPPA. Synapse. John Wiley & Sons Ltd. 2014;68:536–47.PubMedPubMedCentralCrossRef
21.
Lavisse S, García-Lorenzo D, Peyronneau M-A, Bodini B, Thiriez C, Kuhnast B, et al. Optimized quantification of translocator protein radioligand 18F-DPA-714 uptake in the brain of genotyped healthy volunteers. J. Nucl. Med. Society of Nuclear Medicine. 2015;56:1048–54.CrossRef
22.
Guo Q, Colasanti A, Owen DRJ, Onega M, Kamalakaran A, Bennacef I, et al. Quantification of the specific translocator protein signal of 18F-PBR111 in healthy humans: a genetic polymorphism effect on in vivo binding. J. Nucl. Med. Society of Nuclear Medicine. 2013;54:1915–23.CrossRef
23.
Golla SSV, Boellaard R, Oikonen V, Hoffmann A, van Berckel BNM, Windhorst AD, et al. Quantification of [18F]DPA-714 binding in the human brain: initial studies in healthy controls and Alzheimer’s disease patients. J Cereb Blood Flow Metab SAGE Publications. 2015;35:766–72.CrossRef
24.
Rusjan PM, Wilson AA, Bloomfield PM, Vitcu I, Meyer JH, Houle S, et al. Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography. J. Cereb. Blood flow Metab. SAGE PublicationsSage UK: London, England. 2011;31:1807–16.PubMedPubMedCentralCrossRef
25.
Innis R, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9.PubMedCrossRef
26.
Tomasi G, Edison P, Bertoldo A, Roncaroli F, Singh P, Gerhard A, et al. Novel reference region model reveals increased microglial and reduced vascular binding of 11C-(R)-PK11195 in patients with Alzheimer’s disease. J Nucl Med Society of Nuclear Medicine. 2008;49:1249–56.CrossRef
27.
Cosenza-Nashat M, Zhao M-L, Suh H-S, Morgan J, Natividad R, Morgello S, et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol Blackwell Publishing Ltd. 2009;35:306–28.CrossRef
28.
Nutma E, Stephenson JA, Gorter RP, de Bruin J, Boucherie DM, Donat CK, et al. A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis. Brain. 2019;142:3440–55.PubMedPubMedCentralCrossRef
29.
Veronese M, Reis Marques T, Bloomfield PS, Rizzo G, Singh N, Jones D, et al. Kinetic modelling of [11C]PBR28 for 18 kDa translocator protein PET data: a validation study of vascular modelling in the brain using XBD173 and tissue analysis. J Cereb Blood Flow Metab. 2018;38:1227–42.PubMedCrossRef
30.
Turkheimer FE, Edison P, Pavese N, Roncaroli F, Anderson AN, Hammers A, et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J. Nucl. Med. Society of Nuclear Medicine. 2007;48:158–67.
31.
Tournier BB, Tsartsalis S, Ceyzériat K, Medina Z, Fraser BH, Gregoire M, et al. Fluorescence-activated cell sorting to reveal the cell origin of radioligand binding. J. Cereb. Blood Flow Metab. 2019;64:271678X19860408.
32.
Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, Miller JA, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature Nature Publishing Group. 2012;489:391–9.
33.
Wimberley CJ, Lavisse S, Brulon V, Peyronneau M-A, Leroy C, Bodini B, et al. Impact of endothelial TSPO on the quantification of 18F-DPA-714. J. Nucl. Med. Society of Nuclear Medicine; 2017;:jnumed.117.195396.
34.
Rizzo G, Veronese M, Tonietto M, Bodini B, Stankoff B, Wimberley CJ, et al. Generalization of endothelial modelling of TSPO PET imaging: considerations on tracer affinities. J. Cereb. Blood Flow Metab. 2017;8:271678X17742004.
35.
Coughlin JM, Wang Y, Ambinder EB, Ward RE, Minn I, Vranesic M, et al. In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of CSF and plasma. Transl Psychiatry. 2016;6:e777.PubMedPubMedCentralCrossRef
36.
Woodcock EA, Schain M, Cosgrove KP, Hillmer AT. Quantification of [11C]PBR28 data after systemic lipopolysaccharide challenge. EJNMMI Res SpringerOpen. 2020;10:19–6.CrossRef
37.
Hagens MHJ, Golla SV, Wijburg MT, Yaqub M, Heijtel D, Steenwijk MD, et al. In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F]DPA714 PET. J Neuroinflammation BioMed Central. 2018;15:314–0.CrossRef
38.
Todd Ogden R, Zanderigo F, Parsey RV. Estimation of in vivo nonspecific binding in positron emission tomography studies without requiring a reference region. Neuroimage. 2015;108:234–42.PubMedCrossRef
39.
Owen DRJ, Howell OW, Tang S-P, Wells LA, Bennacef I, Bergstrom M, et al. Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab. 2010;30:1608–18.PubMedPubMedCentralCrossRef
40.
Lassen NA, Bartenstein PA, Lammertsma AA, Prevett MC, Turton DR, Luthra SK, et al. Benzodiazepine receptor quantification in vivo in humans using [11C] flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab. 1995;15:152–65.PubMedCrossRef
41.
Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab. 2010;30:46–50.PubMedCrossRef
42.
Ikawa M, Lohith TG, Shrestha S, Telu S, Zoghbi SS, Castellano S, et al. 11C-ER176, a radioligand for 18-kDa translocator protein, has adequate sensitivity to robustly image all three affinity genotypes in human brain. J Nucl Med. 2017;58:320–5.PubMedPubMedCentralCrossRef
43.
Zanotti-Fregonara P, Pascual B, Veronese M, Yu M, Beers D, Appel SH, et al. Head-to-head comparison of 11C-PBR28 and 11C-ER176 for quantification of the translocator protein in the human brain. Eur. J. Nucl. Med. Mol. Imaging. Springer Berlin Heidelberg. 2019;46:1822–9.CrossRef
44.
Schain M, Zanderigo F, Ogden RT, Kreisl WC. Non-invasive estimation of [11C]PBR28 binding potential. Neuroimage. 2018;169:278–85.PubMedCrossRef
45.
Plavén-Sigray P, Schain M, Zanderigo F, Karolinska, Rabiner EA, Gunn RN, et al. Accuracy and reliability of [11C]PBR28 specific binding estimated without the use of a reference region. Neuroimage. 2019;188:102–10.PubMedCrossRef
46.
Schain M, Zanderigo F, Todd Ogden R. Likelihood estimation of drug occupancy for brain PET studies. Neuroimage. 2018;178:255–65.PubMedCrossRef
47.
Everett BA, Oquendo MA, Abi-Dargham A, Nobler MS, Devanand DP, Lisanby SH, et al. Safety of radial arterial catheterization in PET research subjects. J. Nucl. Med. Society of Nuclear Medicine. 2009;50:1742.CrossRef
48.
Zanotti-Fregonara P, Chen K, Liow J-S, Fujita M, Innis R. Image-derived input function for brain PET studies: many challenges and few opportunities. J. Cereb. Blood Flow Metab. SAGE PublicationsSage UK: London, England. 2011;31:1986–98.PubMedPubMedCentralCrossRef
49.
Mabrouk R, Rusjan PM, Mizrahi R, Jacobs MF, Koshimori Y, Houle S, et al. Image derived input function for [18F]-FEPPA: application to quantify translocator protein (18 kDa) in the human brain. Herholz K, editor. PLoS ONE. Public Libr Sci. 2014;9:e115768.CrossRef
50.
Zanotti-Fregonara P, Liow J-S, Fujita M, Dusch E, Zoghbi SS, Luong E, et al. Image-derived input function for human brain using high resolution PET imaging with [C](R)-rolipram and [C]PBR28. Gelovani J, editor. PLoS ONE. Public Libr Sci. 2011;6:e17056.CrossRef
51.
Zanotti-Fregonara P, Hines CS, Zoghbi SS, Liow J-S, Zhang Y, Pike VW, et al. Population-based input function and image-derived input function for [11C](R)-rolipram PET imaging: methodology, validation and application to the study of major depressive disorder. Neuroimage. 2012;63:1532–41.PubMedCrossRef
52.
Mabrouk R, Strafella AP, Knezevic D, Ghadery C, Mizrahi R, Gharehgazlou A, et al. Feasibility study of TSPO quantification with [18F] FEPPA using population-based input function. Garg P, editor. PLoS ONE. Public Libr Sci. 2017;12:e0177785.CrossRef
53.
Lyoo CH, Ikawa M, Liow J-S, Zoghbi SS, Morse CL, Pike VW, et al. Cerebellum can serve as a pseudo-reference region in Alzheimer disease to detect neuroinflammation measured with PET radioligand binding to translocator protein. J. Nucl. Med. Society of Nuclear Medicine. 2015;56:701–6.CrossRef
54.
Kropholler MA, Boellaard R, Schuitemaker A, Folkersma H, van Berckel BNM, Lammertsma AA. Evaluation of reference tissue models for the analysis of [11C](R)-PK11195 studies. J. Cereb. Blood Flow Metab. SAGE Publications. 2006;26:1431–41.CrossRef
55.
Kropholler MA, Boellaard R, van Berckel BN, Schuitemaker A, Kloet RW, Lubberink MJ, et al. Evaluation of reference regions for (R)-[11C]PK11195 studies in Alzheimer’s disease and mild cognitive impairment. Journal of Cerebral Blood Flow & Metabolism. SAGE PublicationsSage UK: London, England. 2007;27:1965–74.CrossRef
56.
Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol. 2009;66:60–7.PubMedPubMedCentralCrossRef
57.
Terada T, Yokokura M, Yoshikawa E, Futatsubashi M, Kono S, Konishi T, et al. Extrastriatal spreading of microglial activation in Parkinson’s disease: a positron emission tomography study. Ann Nucl Med Springer Japan. 2016;30:579–87.CrossRef
58.
Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. Guillemin GJ, editor. PLoS ONE. Public Libr Sci. 2012;7:e52941.CrossRef
59.
Di Biase MA, Zalesky A, O’keefe G, Laskaris L, Baune BT, Weickert CS, et al. PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophrenia. Transl Psychiatry Nature Publishing Group. 2017;7:e1225.CrossRef
60.
Su Z, Herholz K, Gerhard A, Roncaroli F, Plessis Du D, Jackson A, et al. [11C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches. Eur. J. Nucl. Med. Mol. Imaging. Springer Berlin Heidelberg. 2013;40:1406–19.CrossRef
61.
Schuitemaker A, van der Doef TF, Boellaard R, van der Flier WM, Yaqub M, Windhorst AD, et al. Microglial activation in healthy aging. Neurobiol Aging Elsevier. 2012;33:1067–72.CrossRef
62.
Plavén-Sigray P, Matheson GJ, Cselényi Z, Jucaite A, Farde L, Cervenka S. Test-retest reliability and convergent validity of (R)-[11C]PK11195 outcome measures without arterial input function. EJNMMI Res. 3rd ed. SpringerOpen. 2018;8:102–10.PubMedPubMedCentralCrossRef
63.
Kumar A, Muzik O, Shandal V, Chugani D, Chakraborty P, Chugani HT. Evaluation of age-related changes in translocator protein (TSPO) in human brain using (11)C-[R]-PK11195 PET. J Neuroinflammation. BioMed Central. 2012;9:232–11.CrossRef
64.
Albrecht DS, Normandin MD, Shcherbinin S, Wooten DW, Schwarz AJ, Zürcher NR, et al. Pseudoreference regions for glial imaging with 11C-PBR28: investigation in 2 clinical cohorts. J. Nucl. Med. Society of Nuclear Medicine. 2018;59:107–14.CrossRef
65.
Albrecht DS, Forsberg A, Sandström A, Bergan C, Kadetoff D, Protsenko E, et al. Brain glial activation in fibromyalgia - a multi-site positron emission tomography investigation. Brain Behav Immun. 2019;75:72–83.PubMedCrossRef
66.
Zürcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage Clin. 2015;7:409–14.PubMedPubMedCentralCrossRef
67.
Loggia ML, Chonde DB, Akeju O, Arabasz G, Catana C, Edwards RR, et al. Evidence for brain glial activation in chronic pain patients. Brain. 2015;138:604–15.PubMedPubMedCentralCrossRef
68.
Hillmer AT, Sandiego CM, Hannestad J, Angarita GA, Kumar A, McGovern EM, et al. In vivo imaging of translocator protein, a marker of activated microglia, in alcohol dependence. Mol Psychiatry Nature Publishing Group. 2017;22:1759–66.CrossRef
69.
Sandiego CM, Gallezot J-D, Pittman B, Nabulsi N, Lim K, Lin S-F, et al. Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. Proc Natl Acad Sci U S A. 2015;112:12468–73.PubMedPubMedCentralCrossRef
70.
Matheson GJ, Plavén-Sigray P, Forsberg A, Varrone A, Farde L, Cervenka S. Assessment of simplified ratio-based approaches for quantification of PET [11C]PBR28 data. EJNMMI Res. SpringerOpen. 2017;7:58–6.CrossRef
71.
Yaqub M, van Berckel BNM, Schuitemaker A, Hinz R, Turkheimer FE, Tomasi G, et al. Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[(11)C]PK11195 brain PET studies. J Cereb Blood Flow Metab. 2012;32:1600–8.PubMedPubMedCentralCrossRef
72.
Politis M, Giannetti P, Su P, Turkheimer F, Keihaninejad S, Wu K, et al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology. Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 2012;79:523–30.PubMedPubMedCentralCrossRef
73.
Banati RB, Goerres GW, Myers R, Gunn RN, Turkheimer FE, Kreutzberg GW, et al. [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen’s encephalitis. Neurology. Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 1999;53:2199.PubMedCrossRef
74.
Hinz R, Boellaard R. Challenges of quantification of TSPO in the human brain. Clin Transl Imaging Springer Milan. 2015;3:403–16.CrossRef
75.
García-Lorenzo D, Lavisse S, Leroy C, Wimberley CJ, Bodini B, Remy P, et al. Validation of an automatic reference region extraction for the quantification of [18F]DPA-714 in dynamic brain PET studies. J. Cereb. Blood Flow Metab. SAGE PublicationsSage UK: London, England. 2017;266:271678X17692599.
76.
Zanotti-Fregonara P, Kreisl WC, Innis R, Lyoo CH. Automatic extraction of a reference region for the noninvasive quantification of translocator protein in brain using 11C-PBR28. J. Nucl. Med. Society of Nuclear Medicine. 2019;60:978–84.CrossRef
77.
Zanotti-Fregonara P, Pascual B, Rizzo G, Yu M, Pal N, Beers D, et al. Head-to-head comparison of 11C-PBR28 and 18F-GE180 for quantification of the translocator protein in the human brain. J Nucl Med. 2018;59:1260–6.PubMedCrossRef
Metadata
Title
Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain
Authors
Catriona Wimberley
Sonia Lavisse
Ansel Hillmer
Rainer Hinz
Federico Turkheimer
Paolo Zanotti-Fregonara
Publication date
01-12-2021
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-021-05248-9

Other articles of this Issue 1/2021

European Journal of Nuclear Medicine and Molecular Imaging 1/2021 Go to the issue

Review Article

Imaging of the glioma microenvironment by TSPO PET

Review Article

TSPO imaging in animal models of brain diseases

Image of the Month

Accurate detection of intracranial extension of jugulotympanic paraganglioma by [18F]FDOPA-PET/CT comparing to MRI

Original Article

Can the BMI-based dose regimen be used to reduce injection activity and to obtain a constant image quality in oncological patients by 18F-FDG total-body PET/CT imaging?

Review Article

Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: a systematic review and meta-analysis

Review Article

Targeted α-therapy in non-prostate malignancies